Nicotinic acid receptor agonists impair myocardial contractility by energy starvation

William D Watson1, Kerstin N Timm2, Andrew J Lewis1

  • 1Department of Cardiovascular Medicine, Oxford Centre for Clinical Magnetic Resonance Research, University of Oxford, Oxford, UK.

Insights

Nicotinic acid receptor agonists reduce heart contractility by impairing cardiac energetics. This occurs due to reduced fatty acid availability and a failure to increase carbohydrate metabolism, essentially starving the heart of fuel.

Area of Science:

  • Cardiology
  • Metabolic Medicine
  • Biochemistry

Background:

  • Nicotinic acid receptor agonists are known to acutely reduce cardiac contractility.
  • The underlying changes in cardiac metabolism responsible for these functional alterations require further investigation.

Purpose of the Study:

  • To investigate the effects of nicotinic acid on cardiac energetics and function in humans.
  • To explore the impact of a nicotinic acid receptor agonist (Acipimox) on carbohydrate metabolism and cardiac function in rats.

Main Methods:

  • Cardiac MRI and Phosphorus-31 (31P) magnetic resonance spectroscopy were used in humans to assess cardiac function and energetics.
  • Pyruvate dehydrogenase (PDH) flux studies using hyperpolarized Carbon-13 (13C) magnetic resonance spectroscopy were conducted in rats.

Main Results:

  • In humans, nicotinic acid (400 mg) reduced ejection fraction and the phosphocreatine/ATP ratio.
  • In fasted rats, Acipimox decreased ejection fraction and significantly increased PDH flux.
  • In fed rats, Acipimox decreased PDH flux and plasma insulin levels, despite stable glucose concentrations.

Conclusions:

  • Nicotinic acid receptor agonists impair cardiac contractility and energetics.
  • The mechanism involves reduced fatty acid availability and impaired upregulation of carbohydrate metabolism, leading to cardiac "starvation".

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.0K
Cholinergic Receptors: Nicotinic01:15

Cholinergic Receptors: Nicotinic

Nicotinic receptors are ligand-gated ion channels that are activated by acetylcholine and nicotine. Upon activation, they cause a rapid increase in the permeability of cells to K+, Na+, and Ca2+, followed by depolarization and excitation. They are in the autonomic ganglia, skeletal neuromuscular junction, CNS, and adrenal medulla.
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
4.9K
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.4K
Drugs Acting on Autonomic Ganglia: Stimulants01:23

Drugs Acting on Autonomic Ganglia: Stimulants


Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
1.9K
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
2.5K
Drugs Acting on Autonomic Ganglia: Blockers01:28

Drugs Acting on Autonomic Ganglia: Blockers

Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
1.5K